ããã£ããæªããªãç æ°ã瀟äŒãåããââæ ¢æ§çŸæ£ã¯ãªãå人ã®åé¡ã§çµãããªãã®ããâãã£ããæªããªãç æ°âã瀟äŒãåããââæ ¢æ§çŸæ£ã¯ãªãå人ã®åé¡ã§çµãããªãã®ã
ç§ãã¡ã®ç€ŸäŒã¯ä»ããã€ãŠã®ææçãã³ãããã¯ã®ãããªãç®ã«èŠããæ¿æµãã§ã¯ãªããé³ããªãæ°Žäœãäžããç¶ãããéããªæµžæ°Žãã«çŽé¢ããŠããŸãããããæ ¢æ§çŸæ£ã§ãã1幎以äžã®ç¶ç¶çãªæ²»çãšç掻å¶éã匷ãããã®ããã£ããæªããªãç æ°ãã¯ãåãªãå人ã®äžå¹žãäžæçã®çµæã§ã¯ãããŸãããããã¯ããã¯ãçµæžã®å°æ®»å€åãåŽåãã©ãã€ã ã®è»¢æãããã«ã¯ããžã¿ã«æè¡ã«ããå»çã®åå®çŸ©ãè¿«ããçŸä»£ç€ŸäŒã®æ§é ãã®ãã®ã«é¢ããéäœé³ã®ãããªèª²é¡ã§ãããªããäžèŠãéããªç æ°ããæ¥ç ããã瀟äŒå šäœãéãåãããã·ã¹ãã ãæ ¹åºããäœãæ¿ããããšããŠããã®ããæ¬ã¬ããŒãã§ã¯ãææ°ã®çµ±èšããŒã¿ãæ³å¶åºŠã®ååããããŠãã¯ãããžãŒã®é²åãããæ ¢æ§çŸæ£ãå人ã®é åãè¶ ããŠç€ŸäŒã®é£éåå¿ãåŒãèµ·ããã¡ã«ããºã ã詳ããçŽè§£ããŸããç§ãã¡ãçŽé¢ããŠãããæ²é»ã®ãã³ãããã¯ãã®æ£äœãç¥ãããšã¯ã2030幎ã«åããæç¶å¯èœãªç€ŸäŒã®ããæ¹ãèããããã®ãäžå¯æ¬ ãªç¥çåéºãšãªãã¯ãã§ãã
åºè«ïŒæ²é»ã®ãã³ãããã¯ãšç€ŸäŒæ§é ã®å€å®¹
çŸä»£ç€ŸäŒã«ãããå¥åº·ã®å®çŸ©ãšããããè
ãããªã¹ã¯ã®æ¬è³ªã¯ãéå»1äžçŽã®éã§åçãªè»¢æãéããããã€ãŠäººé¡ã®æå€§ã®è
åšã§ãã£ãæ¥æ§ææçã飢é€ã¯ãå
¬è¡è¡çã®æ¹åãæ é€ç¶æ
ã®åäžããããŠæçç©è³ªãã¯ã¯ãã³ã®æ®åã«ãã£ãŠå¶åŸ¡å¯èœãªãã®ãžãšå€ãããããã«ä»£ãã£ãŠãæ
¢æ§çŸæ£ïŒChronic DiseasesïŒãããããã¯éæææ§çŸæ£ïŒNCDsïŒãæ¯é
çãªå°äœãå ããããã«ãªã£ããæ
¢æ§çŸæ£ã¯ãäžè¬ã«1幎以äžã®ç¶ç¶çãªå»çä»å
¥ãçæŽ»äžã®å¶éãå¿
èŠãšããç¶æ
ãæãããã®é²è¡ã¯ç·©ããã§ãæã«ã¯ãæ²é»ããä¿ã¡ãªããå人ã®èº«äœã䟵é£ããŠããã
ãããããã®ããã£ãããšæªããªãããšããæ§è³ªããããçŸä»£ç€ŸäŒã«æ·±å»ãªæ§é çè² è·ãäžããŠãããæ¥æ§ã®ç
æ
ãäžæçãªãªãœãŒã¹ã®éäžæäžã«ãã£ãŠè§£æ±ºå¯èœã§ããã®ã«å¯Ÿããæ
¢æ§çŸæ£ã¯ãå人ã®ç涯ã«ãããQOLïŒç掻ã®è³ªïŒã®äœäžãæãã ãã§ãªããå»ççµæžãåŽååžå Žãå®¶æå¶åºŠããããŠæ¬¡äžä»£ã®æè²æ©äŒã«è³ããŸã§ã瀟äŒã®ããããã¬ãã«ã§è€éãªé£éåå¿ãåŒãèµ·ããããã§ããã
æ¬å ±åæžã§ã¯ãæ
¢æ§çŸæ£ããªãåãªãå人ã®å¥åº·åé¡ãšããé åãè¶
ãã瀟äŒå
šäœãéãåãããã¯ããªèª²é¡ãšãªã£ãŠããã®ãããææ°ã®çµ±èšããŒã¿ãæ³å¶åºŠã®å€é·ããã¯ãããžãŒã®é²åããããŠç€ŸäŒåŠçãªçè«èæ¯ããå€è§çã«åæãããç¹ã«ãè¿å¹Žã®æ°åã³ãããŠã€ã«ã¹ææçïŒCOVID-19ïŒã®ãã³ãããã¯ãæµ®ã圫ãã«ããã眹æ£åŸçç¶ïŒãã³ã°COVIDïŒããšããæ°ããªæ
¢æ§çŸæ£ã®ãããã¿ã€ãã軞ã«ã2025幎ãã2030幎ã«ãããŠã®ç€ŸäŒæ§é ã®ååã屿ããã
æ ¢æ§çŸæ£ããããããã¯ãçµæžã®å°æ®»å€å
æ ¢æ§çŸæ£ã®åœ±é¿ãè©äŸ¡ããéãåŸæ¥ã®å»çã¢ãã«ã§ã¯ãçŽæ¥çãªå»çè²»ïŒå ¥é¢è²»ãè¬ä»£ïŒã«çŠç¹ãåœãŠãããã¡ã§ãã£ããããããææ°ã®çµæžåŠçç¥èŠã¯ããã®èåŸã«æœãã鿥çã³ã¹ããããçŽæ¥å»çè²»ãé¥ãã«åé§ããèŠæš¡ã§çµæžãå§è¿«ããŠããããšã瀺ããŠããã
çŽæ¥çå»çè²»ã®æ§é çå¢å€§
çµæžååéçºæ©æ§ïŒOECDïŒã®ææ°ã®å ±åã«ããã°ããã³ã°COVIDãäŸã«åã£ãå Žåã2021幎ã®ããŒã¯æã«ãããOECD諞åœã®çŽæ¥çãªå»çè²»æ¯åºã¯çŽ530åãã«ã«éãããããã¯å
šå»çæ¯åºã®çŽ0.6%ãã0.8%ãå ããèŠæš¡ã§ãããäžèŠãããšéå®çã«èŠãããããããªãããããããã®å
èš³ã詳现ã«èŠããšãæ
¢æ§çŸæ£ç¹æã®è² è·ãèŠããŠããã
è±åœã®åœæ°ä¿å¥ãµãŒãã¹ïŒNHSïŒã«ããã調æ»ã§ã¯ããã³ã°COVIDæ£è
ã®äžè¬èšºçïŒGPïŒã倿¥ãå
¥é¢ãææ¥ã±ã¢ã®å©çšã¯ãçç¶ã®ãªã察ç
§çŸ€ãšæ¯èŒããŠãçºçãã2幎ãçµéããŠããªã40%以äžé«ãç¶æ
ãç¶ç¶ããŠããããŸããç±³åœã«ãããä¿éºéè«æ±ããŒã¿ã®åæã§ã¯ãææåŸ1幎éã®å»çè²»ãã察ç
§çŸ€ãã1人ãããå¹³å9,400ãã«ïŒçŽ45%å¢ïŒé«ãããšã倿ããããã®æ¯åºå¢ã®äž»å ã¯ãåãªãéé¢ã§ã¯ãªããå¿è¡ç®¡ãåŒåžåšãã¡ã³ã¿ã«ãã«ã¹ã®å䜵çã«äŒŽãåå
¥é¢ãå°éçãªãã©ããŒã¢ããã§ããããã®ããã«ãæ
¢æ§çŸæ£ã¯å»çã·ã¹ãã ã«å¯ŸããŠãäžæçãªããŒã¯ãã§ã¯ãªããæä¹
çãªããŒã¹ã©ã€ã³ã®åºäžããã匷ããã®ã§ããã
鿥ççµæžæå€±ïŒãã¬ãŒã³ãã£ãŒã€ãºã ã®è åš
æ
¢æ§çŸæ£ãçã«ç€ŸäŒããéãåãããèŠå ã¯ãåŽåçç£æ§ã®äœäžã«äŒŽãè«å€§ãªéæ¥ã³ã¹ãã«ãããOECDã®è©Šç®ã«ããã°ã2021幎ã«ããããã³ã°COVIDã«é¢é£ãã鿥çãªçµæžæå€±ã¯çŽ6,800åãã«ã«åã³ãããã¯çŽæ¥çãªå»çè²»ã®çŽ13åãšããå·šé¡ãªãã®ã§ããã
ãã®æå€±ã®ã¡ã«ããºã ãçè§£ããããã«ã¯ããã¢ãã»ã³ãã£ãŒã€ãºã ïŒæ¬ å€ïŒãã ãã§ãªããããã¬ãŒã³ãã£ãŒã€ãºã ïŒçŸç
å°±æ¥ïŒãã®æŠå¿µãå°å
¥ããå¿
èŠããããæ
¢æ§çŸæ£æ£è
ã®å€ãã¯ãå®å
šã«åŽååžå Žããéåºããããã§ã¯ãªããããããç²åŽãèªç¥æ©èœã®äœäžïŒãã¬ã€ã³ãã©ã°ïŒãçŒçãªã©ãæ±ãããŸãŸå°±æ¥ãç¶ããããšã§ãæ¬æ¥ã®ããã©ãŒãã³ã¹ãçºæ®ã§ããªãç¶æ
ã«é¥ãã

OECDã®æåœ±ã«ããã°ã2025幎ãã2035幎ã«ãããŠããã³ã°COVIDã ãã§ãOECD諞åœã®GDPãæ¯å¹Ž0.1%ãã0.2%æŒãäžãããšäºæž¬ãããŠãããããã¯ãªã©ã³ãã®å¹Žéä¿å¥äºç®å šäœã«å¹æµããèŠæš¡ã®æå€±ã§ãããäœæé·ãšäººå£é«éœ¢åã«çŽé¢ããå é²è«žåœã«ãšã£ãŠãç¡èŠã§ããªãçµæžçè¶³ãããšãªã£ãŠããã
æ¥æ¬ã«ãããåŽåã»çµå¶ãã©ãã€ã ã®è»¢æ
æ ¢æ§çŸæ£ã瀟äŒãåããå ·äœçãªäžäŸãšããŠãæ¥æ¬ã«ããããæ²»çãšä»äºã®äž¡ç«æ¯æŽãã«åããæ³çã»ç€ŸäŒçå€åãæãããããæ·±å»ãªäººæäžè¶³ã«çŽé¢ããæ¥æ¬ç€ŸäŒã«ãšã£ãŠãçŸç ãæ±ããåŽåè ã®å°±æ¥ç¶ç¶ã¯ããã¯ãçŠå©åçã®åãè¶ ããçµå¶äžã®çåæŠç¥ãšãªã£ãŠããã
2026幎åé¡ïŒäž¡ç«æ¯æŽã®åªå矩åå
2025å¹Žã«æ¹æ£ããããåŽåæœçç·åæšé²æ³ïŒä»€å7幎æ³åŸç¬¬63å·ïŒãã«åºã¥ãã2026幎4æ1æ¥ããããã¹ãŠã®äºæ¥äž»ã«å¯ŸããŠãè·å Žã«ãããæ²»çãšå°±æ¥ã®äž¡ç«æ¯æŽããåªå矩ååããããããã¯ããããè³åäžãå¿çŸæ£ãç³å°¿ç
ãé£ç
ãšãã£ãæ
¢æ§çãªæ²»çãèŠããåŽåè
ããé©åãªãµããŒããåããããã«é¢è·ããããšãé²ãããã®æŽå²çãªæ³ç転æã§ããã
äŒæ¥ã«æ±ãããã察å¿ã¯å€å²ã«ããããåãªãäŒæå¶åºŠã®æ¡å
ã«çãŸããªããåçåŽåçã®æéã«ããã°ã以äžã®4ã€ã®æ±ãäžå¿ãšããç°å¢æŽåãæšå¥šãããŠããã
ãããã«ããæ¹é衚æ: çŸç
ãæ±ããåŽåè
ãçµç¹ãšããŠæ¯æŽããå§¿å¢ãæç¢ºã«ãã瀟å
ã®æèåçºãè¡ãã
çžè«çªå£ã𿝿Žäœå¶: çžè«çªå£ãæç¢ºåãããäž¡ç«æ¯æŽã³ãŒãã£ããŒã¿ãŒããªã©ã®å°éå®¶ãä»ããŠã䞻治å»ãç£æ¥å»ã人äºéšéã飿ºããäœå¶ãæ§ç¯ããã
æè»ãªå€åå¶åºŠ: æéåäœã®æçµŠäŒæãç
æ°äŒæãæå·®åºå€ïŒãã¬ãã¯ã¹ïŒããã¬ã¯ãŒã¯ãçæéå€åãªã©ãæ²»çã¹ã±ãžã¥ãŒã«ã«åãããæè»ãªåãæ¹ãå°å
¥ããã
æ
å ±ã®æšæºå: 䞻治å»ããäŒç€Ÿãžã®ãäž»æ²»å»æèŠæžãããäŒç€Ÿãã䞻治å»ãžã®ãå€åæ
å ±æäŸæžããæŽ»çšãããšããã³ã¹ã«åºã¥ããå°±æ¥äžã®æªçœ®ã決å®ããã
ãã®å€åã¯ãæ¥æ¬ã®äŒæ¥æåã«ããããå¥åº·ãã®æãæ¹ãæ ¹æ¬ããå€ãã€ã€ããããã€ãŠã¯ãç æ°ã«ãªã£ããäŒãããããã¯èŸããããšããäºè æäžã§ãã£ãããããããã¯ãç æ°ãæ±ããªãããããã«çµç¹ã«è²¢ç®ãç¶ãããããšããã°ã©ããŒã·ã§ã³ã®ããå°±æ¥ã¢ãã«ãæšæºãšãªãã
å¥åº·çµå¶ã®é«åºŠåãšããã¯ã¹ããã©ã€ã1000ã
çµæžç£æ¥çãæšé²ãããå¥åº·çµå¶ïŒHealth and Productivity ManagementïŒããããã®æ
¢æ§çŸæ£ã®æ³¢ãåããŠãããªãåºãããèŠããŠããã2024幎床ã®èªå®æ³äººã§åãåŸæ¥å¡æ°ã¯çŽ991äžäººã«éããæ¥æ¬ã®è¢«éçšè
ã®çŽ16%ãå ããèŠæš¡ãšãªã£ããããã«ãæ¥çµå¹³åæ ªäŸ¡ãæ§æãã225瀟ã®çŽ8å²ãå¥åº·çµå¶åºŠèª¿æ»ã«åçãããªã©ãå€§äŒæ¥ã«ãããŠã¯ãå¥åº·ããæè³å®¶ãžã®éèŠãªé瀺æ
å ±ãšãªã£ãŠããã
2024幎床ããã¯ãç¹ã«äžå°äŒæ¥ã察象ãšããæ°ããªã«ããŽãªãŒãšããŠããã¯ã¹ããã©ã€ã1000ããæ°èšããããããã¯ãæ¢åã®ããããã£ã¢ã§ããããã©ã€ã500ãã®äžäœã«äœçœ®ããå°æ¥çã«å°åãæ¥çã®ããŒã«ã¢ãã«ãšãªãããšãæåŸ
ããã1,000瀟ãèªå®ããå¶åºŠã§ããããã®å¶åºŠã®å°å
¥ã«ãããå¥åº·çµå¶ã¯ã宿œããããšèªäœãç®çãã§ããããã»ã¹è©äŸ¡ã®æ®µéãããé¢è·çã®äœäžãåŽåçç£æ§ã®åäžãšãã£ããå
·äœçãªçµå¶ææããåãã¢ãŠãã«ã è©äŸ¡ã®æ®µéãžãšç§»è¡ããŠããã

ãã®ãããªãã¬ã³ãã¯ãæ ¢æ§çŸæ£ããå人ã®äžæçã®çµæãã§ã¯ãªããã瀟äŒå šäœã§ç®¡çãã¹ãçµå¶è³æºããšããŠåå®çŸ©ãããããšã瀺ããŠããã
ãã¯ãããžãŒã«ããæ ¢æ§çŸæ£ç®¡çã®åæ§ç¯
æ ¢æ§çŸæ£ã®ããã£ãããšãããã確å®ã«é²è¡ããããšããç¹æ§ã¯ãåŸæ¥ã®å¯Ÿé¢åã»ã¹ãããçãªèšºçã¢ãã«ãšã¯æ¥µããŠçžæ§ãæªãããã®ã®ã£ãããåããããã«ç»å Žããã®ããAIé§åã®ããžã¿ã«ã»ã»ã©ãã¥ãŒãã£ã¯ã¹ïŒDTxïŒããžã¿ã«æ²»çïŒãšãé«åºŠãªã¢ãã¿ãªã³ã°æè¡ã§ããã
ããžã¿ã«ã»ã»ã©ãã¥ãŒãã£ã¯ã¹ïŒDTxïŒã®èšåºçã€ã³ãã¯ã
DTxã¯ããœãããŠã§ã¢ãçšããŠçŸæ£ãæ²»çã管çãäºé²ããæ°ããæ²»çã¢ããªãã£ã§ããããšããã³ã¹ã«åºã¥ããèšåºçãªä»å ¥ãæäŸããã2025幎以éã®ãã¬ã³ããšããŠãAIãæŽ»çšããåå¥åã±ã¢ãå éããŠãããææ°ã®ç ç©¶ã«ããã°ãAIé§åã®DTxãã©ãããã©ãŒã ã¯ä»¥äžã®ãããªåçãªææãå ±åããŠããã
2åç³å°¿ç
: HbA1cïŒéå»1-2ã¶æã®è¡ç³ç¶æ
ãç€ºãææšïŒãå¹³åã§0.67%åæžããããšã«æåã
é«è¡å§: 3幎éã«ããããæ£è
ã®84%ãç®æšãšããè¡å§ã³ã³ãããŒã«ãç¶æã
ã¡ã³ã¿ã«ãã«ã¹: ãã€ç
ã®ææšã§ããPHQ-9ã¹ã³ã¢ã«ãããŠãå¹³å7.3ãã€ã³ãã®æ¹åãå®çŸã
ãããã®ããžã¿ã«ããŒã«ã¯ãã¹ããŒããã©ã³ããŠã§ã¢ã©ãã«ããã€ã¹ãéããŠã24æé365æ¥ã®ã¢ãã¿ãªã³ã°ãå¯èœã«ãããäŸãã°ãå€ãã®ç³å°¿ç åãDTxã¢ããªã¯ãBluetoothçµç±ã§è¡ç³æž¬å®åšãšåæããç°åžžãªå€ãæ€ç¥ããç¬éã«AIãã¢ãããŒã·ã§ã³åäžã®ã¡ãã»ãŒãžãå ·äœçãªè¡åæç€ºãéä¿¡ãããããã¯ãæ°ã¶æã«äžåºŠã®é颿ã«å»åž«ããåããæå°ããããæ£è ã®è¡åå€å®¹ã«å¯ŸããŠé¥ãã«åŒ·åãªåœ±é¿ãåãŒãã
ãã€ãã®DiGAã¢ãã«ïŒåœå®¶ã¬ãã«ã®ç€ŸäŒå®éš
æ
¢æ§çŸæ£ç®¡çã«ãããŠãããžã¿ã«æè¡ãããã«ç€ŸäŒå¶åºŠãåãããã瀺ãæè¯ã®äŸã¯ããã€ãã®ãDiGAïŒããžã¿ã«å¥åº·ã¢ããªã±ãŒã·ã§ã³ïŒãããã°ã©ã ã§ããã2019幎ã®ããžã¿ã«ãã«ã¹æ³ïŒDVGïŒã«ããããã€ãã¯äžçã«å
é§ããŠãç¹å®ã®ããžã¿ã«ã¢ããªããå»åž«ãåŠæ¹ããå
¬çå»çä¿éºãå
šé¡åéãããä»çµã¿ãæ§ç¯ããã
ãã®å¶åºŠã®é©æ°æ§ã¯ã蚌æ ã®åµåºãåæãšããã¢ã¯ã»ã¹ããšããææ³ã«ãããDiGAãšããŠèªå®ãããããã«ã¯ãèšåºçãªãããã£ããã®èšŒæãå¿
èŠã ããããŒã¿ãäžååãªå Žåã§ãã12ã¶æã®ç¶äºæéå
ã«èšåºè©Šéšã宿œããããšãæ¡ä»¶ã«ãä»®ç»é²ããšããŠä¿éºé©çšãåããããšãã§ããã2024幎åã°ãŸã§ã«40以äžã®DiGAããã®ããã»ã¹ãééãããã®çŽ4å²ã粟ç¥çŸæ£ïŒäžå®é害ããã€ç
ïŒã察象ãšããŠããã
ãã®ã¢ãã«ã¯ã以äžã®3ã€ã®æ¬¡å
ã§å»çè³æºã®é
åãå¹çåããã
ã¢ã¯ã»ã¹ã®å¹³æºå: å°éå»ã®äžè¶³ãé·ãåŸ
æ©æéã課é¡ãšãªã£ãŠããã¡ã³ã¿ã«ãã«ã¹é åã«ãããŠãå³åº§ã«æ²»çãéå§ã§ããä»£æ¿ææ®µãæäŸããã
ã³ã¹ãã®éæå: ã¢ããªã®äŸ¡æ Œã¯åœåã¡ãŒã«ãŒãèšå®ãããããã®åŸã®å¹ææ€èšŒã®çµæã«åºã¥ããä¿éºè
ãšã®äŸ¡æ Œäº€æžãè¡ããããããã«ããã广ã®ãªãããžã¿ã«ããŒã«ãåžå Žã«æ®ãç¶ããããšãé²ãã§ããã
åŽååãžã®éå
: æ
¢æ§çãªè
°çã管çããDiGAãªã©ã¯ãçåŠçæ³ã®ã¬ã€ããéããŠæ©æã®è·å ŽåŸ©åž°ãä¿ãã鿥çãªçµæžæå€±ã®æå¶ã«å¯äžããŠããã
äžçåžå Žã«ãããŠããDTxåžå Žã¯2025幎ãã2032幎ã«ãããŠ28.3%ãšããæ¥µããŠé«ã幎平åæé·çïŒCAGRïŒã§æ¡å€§ãã2032幎ã«ã¯544åãã«èŠæš¡ã«éãããšäºæž¬ãããŠãããæ ¢æ§çŸæ£ã¯ä»ããããžã¿ã«æè¡ãå»çã®äžæ žãžãšåŒãå¯ããæå€§ã®æšé²åãšãªã£ãŠããã
å¥åº·ã®ç€ŸäŒç決å®èŠå ïŒSDOHïŒïŒæ Œå·®ã®å°çåŠ
æ ¢æ§çŸæ£ãå人ã®åé¡ã§çµãããªãæãæ·±å»ãªçç±ã¯ããããã瀟äŒã®äžå ¬æ£ãã®çµæãšããŠçºçããããã«ãã®äžå ¬æ£ãå¢å¹ ãããããã§ãããäžçä¿å¥æ©é¢ïŒWHOïŒã2025幎5æã«çºè¡šãããå¥åº·ã®å ¬å¹³æ§ã«é¢ããäžçå ±åæžãã¯ãç§ãã¡ã®å¥åº·ãããã«éºäŒåãå人ã®åªåã§ã¯ãªããçæŽ»ç°å¢ïŒå¥åº·ã®ç€ŸäŒç決å®èŠå ïŒSDOHïŒã«ãã£ãŠæ±ºå®ãããŠããããè¡æçãªããŒã¿ã§ç€ºããŠããã
寿åœã奪ã33å¹Žã®æ Œå·®
å ±åæžã«ããã°ãäžçã§æãå¹³å寿åœãé·ãåœãšçãåœã®éã«ã¯ãå®ã«33幎ãã®æ Œå·®ãååšããããã®å·®ãçãã§ããã®ã¯ãå»çãžã®ã¢ã¯ã»ã¹ã ãã§ã¯ãªãããããã以äžã®ãããªãéå»åŠçãªæ ¹æ¬åå ããæ ¢æ§çŸæ£ã®çºçãªã¹ã¯ãèŠå®ããŠããã

ç¹ã«ãæåŸæ Œå·®ã¯éå»20幎éã§æ¥æ¡å€§ããŠãããå€ãã®åœã§ãåœå ã®æ Œå·®ãããåœåå£«ã®æ Œå·®ããäžåãäž»èŠãªå¥åº·æ Œå·®ã®èŠå ãšãªã£ãŠãããè²§å°å±€ã»ã©è¶ å å·¥é£åãã¿ãã³ãã¢ã«ã³ãŒã«ãšãã£ããäžå¥åº·ãªè£œåïŒåæ¥ç決å®èŠå ïŒãã«æãããããããããç³å°¿ç ãå¿è¡ç®¡çŸæ£ãšãã£ãæ ¢æ§çŸæ£ãèªçºããçµæãšããŠãããªãçµæžçå°çª®ãæããšããè² ã®ã¹ãã€ã©ã«ã圢æãããŠããã
æ°åå€åãšæ°ããªå¥åº·æ Œå·®
2025幎ã®èŠç¹ã«ãããŠç¡èŠã§ããªãã®ããæ°åå€åãããããæ
¢æ§çŸæ£ã®å¢å€§ã§ãããWHOã®æšèšã«ããã°ãæ°åå€åã¯ä»åŸ5幎éã§6,800äžãã1å3,500äžäººã極床ã®è²§å°ã«è¿œããããªã¹ã¯ãããããããæ°ããªæ
¢æ§çŸæ£ã®æ³¢ãçããšäºæž¬ãããŠãããç±æ³¢ã«ãã埪ç°åšç³»ãžã®è² æ
ãå€§æ°æ±æã®æªåã«ããåŒåžåšçŸæ£ã®å¢å ããããŠçœå®³ã«äŒŽãã¡ã³ã¿ã«ãã«ã¹ã®æªåã¯ã瀟äŒçã«è匱ãªã³ãã¥ããã£ãçŽæããã
æ
¢æ§çŸæ£ã¯ããã¯ããå人ã®çæŽ»ç¿æ
£ããšããæ çµã¿ã§ã¯æããããªããããã¯ã瀟äŒãè³æºãæ©äŒãã©ã®ããã«åé
ããç°å¢ãªã¹ã¯ãã©ã®ããã«ç®¡çããŠãããã瀺ããæ¥µããŠæ¿æ²»çãã€ç€ŸäŒçãªææšãªã®ã§ããã
次äžä»£ã®ç ç²ïŒã€ã³ã°ã±ã¢ã©ãŒãšããæ²é»ã®åŽåå
æ ¢æ§çŸæ£ã®é·æåã瀟äŒã«åãŒã圱é¿ã®ãã¡ãæãç®ã«èŠãã«ããããã€ç Žå£çãªãã®ããã€ã³ã°ã±ã¢ã©ãŒãåé¡ã§ãããããã¯ãæ ¢æ§çŸæ£ãæ±ããå®¶æã®ããã«ãæ¬æ¥å€§äººãæ ãã¹ãå®¶äºãä»è·ãææ çãªãµããŒããæ¥åžžçã«è¡ã£ãŠããåã©ããã¡ã®ååšãæãã
æ¥æ¬ã®å®æ ïŒ17人ã«1人ã®çŸå®
æ¥æ¬ã«ãããææ°ã®èª¿æ»ã«ããã°ãã€ã³ã°ã±ã¢ã©ãŒã®å²åã¯äžåŠ2幎çã§5.7%ïŒçŽ17人ã«1人ïŒã髿 ¡2幎çã§4.1%ïŒçŽ24人ã«1人ïŒã«éããŠãããå°åŠæ ¡6幎çã§ã6.5%ã®åã©ãããå®¶æã®äžè©±ãããŠããããšåçããŠãããè¥å¹Žå±€ã«ãããã±ã¢ã®è² æ
ã¯åºç¯ã«åãã§ããã
ã±ã¢ã®å
容ã¯ãæçãæŽæ¿¯ãšãã£ãå®¶äºããã幌ããããã ãã®äžè©±ãããã«ã¯ç
æ°ã®èŠªã®éé¢ä»ãæ·»ããææ
çãªèŠå®ããŸã§å€å²ã«ããããå¹³æ¥1æ¥ãããã«è²»ããæéã¯å¹³åã§4æéååŸã«åã¶ããæ·±å»ãªã±ãŒã¹ã§ã¯ã1æ¥7æé以äžããã±ã¢ã«è²»ããçåŸã1å²ãè¶
ããŠããã

å°æ¥ãžã®äžå¯éçãªãã¡ãŒãž
ã€ã³ã°ã±ã¢ã©ãŒåé¡ã®æ žå¿ã¯ãæ
¢æ§çŸæ£ããåã©ããã¡ã®å°æ¥ã®å¯èœæ§ããç¡æèã®ãã¡ã«å¥ªãå»ãããšã«ãããäžè©±ãããŠããåã©ãã¯ãããŠããªãåã©ãã«æ¯ã¹ãŠãå¥åº·ç¶æ
ãè³ãããªããé
å»ãæ¬ åžãå€ãã宿é¡ãã§ããªããšãã£ãåŸåã2å以äžé«ãããšã瀺ãããŠããã
ããã«æ·±å»ãªã®ã¯ãé«çæè²ããã£ãªã¢åœ¢æãžã®åœ±é¿ã§ããã倧åŠçã察象ãšããã¢ã³ã±ãŒãã§ã¯ãå®¶æã®äžè©±ãããŠããåŠçã®çŽ50%ããå°±è·ãé²è·¯ã«ã€ããŠäœããã®äžå®ãæ±ããŠãããå
·äœçã«ã¯ããåéšååŒ·ã®æéãåããªãã£ãããåŠè²»çã®å¶çŽãçµæžçäžå®ããã£ãããå®å®¶ããéããç¯å²ã«å€§åŠãéžã°ãããåŸãªãã£ãããšãã£ã声ãäžãã£ãŠããã
ããã¯ã芪äžä»£ã®æ
¢æ§çŸæ£ããåäžä»£ã®æè²æ©äŒã®åªå€±ãšç€ŸäŒçæµåæ§ã®äœäžãæããè²§å°ãšç
ã®é£éãåºå®åãããŠããããšãæå³ãããæ
¢æ§çŸæ£ãå人ã®åé¡ã§çµãããªãã®ã¯ãããããå®¶æããšããå¯å®€ãéããŠã次äžä»£ã®äººçè³æ¬ãæ¯æãã瀟äŒå
šäœã®æŽ»åãåãããã§ããã
ç«åŠç転æçè«ïŒæŽå²ã®å¿ ç¶ãšããŠã®æ ¢æ§çŸæ£
æ ¢æ§çŸæ£ããªãããã»ã©ãŸã§ã«çŸä»£ç€ŸäŒãéãåããã®ããçè§£ããããã«ã¯ãã¢ããã«ã»ãªã ã©ã³ïŒAbdel OmranïŒã1971å¹Žã«æå±ãããç«åŠç転æïŒEpidemiological TransitionïŒãçè«ã«ç«ã¡è¿ãå¿ èŠãããããã®çè«ã¯ã瀟äŒã®çºå±ã«äŒŽãã人ã ã®æ»å ãçŸç ãã¿ãŒã³ãã©ã®ããã«å€åãããã説æããŠããã
äžæ®µéã®ã¢ãã«ãšã人工ççŸæ£ã
ãªã ã©ã³ã¯ã人é¡ã®å¥åº·ã®æŽå²ã以äžã®äžã€ã®æ®µéã«åããã
ç«ç
ãšé£¢é€ã®æä»£ (The Age of Pestilence and Famine): æ»äº¡çãé«ãå€åããææçãå¯çè«ãæ é€äžè¶³ãäž»å ãšãªããäººå£æé·ã¯åæ»ããå¹³å寿åœã¯20ïœ40幎ã§ããã
ãã³ãããã¯åŸéã®æä»£ (The Age of Receding Pandemics): èŸ²æ¥æè¡ã®åäžãå
¬è¡è¡çã®æ¹åã«ãããå€§èŠæš¡ãªç«ç
ãæžå°ãããæ»äº¡çã¯äœäžãå§ãã人å£ãççºçã«å¢å ããã
倿§ã»äººçºççŸæ£ã®æä»£ (The Age of Degenerative and Man-made Diseases): ææçã«ä»£ãããå¿è¡ç®¡çŸæ£ããããç³å°¿ç
ãªã©ã®æ
¢æ§ã»å€æ§çŸæ£ãæ»å ã®äž»æµãšãªãã
ããã§æ³šç®ãã¹ãã¯ãç¬¬äžæ®µéã«ãããçŸæ£ãã人çºçïŒMan-madeïŒããšåœ¢å®¹ãããŠããç¹ã§ãããæ ¢æ§çŸæ£ã¯ãé·å¯¿åãšãã人é¡ã®èŒãããæåã®çµæã§ãããšåæã«ãéœåžåãé£çæŽ»ã®æ¬§ç±³åãéåäžè¶³ãç°å¢æ±æãã¹ãã¬ã¹ãšãã£ããçŸä»£ææã®ã©ã€ãã¹ã¿ã€ã«ãã®ãã®ããçã¿åºããç çã§ããã
çŸä»£ã®è€éæ§ïŒç¬¬äºã®æ®µéãž
1983幎以éããªã ã©ã³ããã®åŸã®ç ç©¶è
ãã¡ã¯ããã®çè«ãããã«æ¡åŒµããŠãããçŸåšãç§ãã¡ã¯æ
¢æ§çŸæ£ãæ¯é
çãªã第åã®æ®µéïŒå»¶æããã倿§çŸæ£ã®æä»£ïŒããçµãŠãããã«è€éãªã第äºã®æ®µéãã«è¶³ãèžã¿å
¥ããŠããå¯èœæ§ãããã
ãã®æ°ããæ®µéã®ç¹åŸŽã¯ãè¥æºãéåäžè¶³ãšãã£ããæ°ããªçæŽ»ç¿æ
£ãªã¹ã¯ãã®å°é ãšãæèè¬èæ§èãæ°ããªãã³ãããã¯ïŒCOVID-19çïŒã®ãããªãåèææçãããæ¢åã®æ
¢æ§çŸæ£ãšè€éã«çµ¡ã¿åãç¹ã«ãããçŸä»£ã®ç€ŸäŒæ§é ã¯ãæ
¢æ§çŸæ£ãæ±ããªããé«éœ¢æãéããèšå€§ãªäººå£ãæ¯ããããã«èšèšãããŠãããããã®ã転æã®å®äºããšã瀟äŒå¶åºŠã®æªå¯Ÿå¿ãã®éã®ã®ã£ããããçŸåšã®æªã¿ãçãã§ããã®ã§ããã
çµè«ïŒæç¶å¯èœãªç€ŸäŒãžã®æ§é çã¬ãžãªãšã³ã¹ã®æ§ç¯
æ ¢æ§çŸæ£ã¯ããã®é²è¡ã®ç·©æ ¢ãããã«ããã€ãŠã®é»æ»ç ãã³ã¬ã©ã®ãããªåçãªææã瀟äŒã«äžããããšã¯ãªããããããæ¬å ±åæžã®èª¿æ»ã瀺ããéããæ ¢æ§çŸæ£ã¯ãæ²é»ã®ãã³ãããã¯ããšããŠãçµæžãåŽåãæè¡ã瀟äŒå ¬å¹³æ§ããããŠæ¬¡äžä»£ã®éåœãšãã5ã€ã®è»žãéããŠã瀟äŒãæ ¹åºããéãåãããŠããã
çµæžçã¬ãžãªãšã³ã¹: çŽæ¥å»çè²»ã®13åã«åã¶éæ¥ççµæžæå€±ïŒãã¬ãŒã³ãã£ãŒã€ãºã ïŒãæå¶ããããã«ã¯ãäŒæ¥ã¯åŽåè
ã®å¥åº·ããã³ã¹ããã§ã¯ãªããè³æ¬ããšããŠæãçŽãå¿
èŠããããæ¥æ¬ã®ãå¥åº·çµå¶ããäž¡ç«æ¯æŽã®åªå矩ååã¯ããã®äžå¯é¿ãªæ¹åæ§ã瀺ããŠããã
æè¡çã¬ãžãªãšã³ã¹: DTxãAIãæŽ»çšããæ
¢æ§çŸæ£ã®åå¥å管çã¯ãç
é¢å®çµåã®å»çã¢ãã«ãããçæŽ»å¯çåãã®å»çã¢ãã«ãžã®è»¢æãå¯èœã«ããããã€ãã®DiGAã¢ãã«ã®ãããªå¶åºŠçæ¯æŽããæè¡ã®ç€ŸäŒå®è£
ãå éãããéµãšãªãã
瀟äŒçã¬ãžãªãšã³ã¹: å¥åº·ã®ç€ŸäŒç決å®èŠå ïŒSDOHïŒãžã®ä»å
¥ãªãã«ãæ
¢æ§çŸæ£ã®è² æ
ã軜æžããããšã¯äžå¯èœã§ãããæåŸæ Œå·®ã®æ¯æ£ãæè²ã®æ©äŒåçããããŠæ°åå€å察çã¯ãåºçŸ©ã®ãå
¬è¡è¡çæ¿çããšããŠåå®çŸ©ãããã¹ãã§ããã
äžä»£éã®ã¬ãžãªãšã³ã¹: ã€ã³ã°ã±ã¢ã©ãŒåé¡ã®è§£æ¶ã¯ãåãªãçŠç¥ã®èª²é¡ã§ã¯ãªããå°æ¥ã®åŽååãšç€ŸäŒã®æç¶å¯èœæ§ãå®ãããã®æè³ã§ãããæ
¢æ§çŸæ£ãæ±ããå®¶æãžã®å
¬çãªãµããŒãäœå¶ãæ§ç¯ããåã©ããã¡ã®æè²æ©äŒãä¿è·ããããšãæ¥åã§ããã
æ ¢æ§çŸæ£ãå人ã®åé¡ã§çµãããªãã®ã¯ããããç§ãã¡ã®ææã®ããæ¹ãã®ãã®ãçã¿åºãããè² ã®å€éšæ§ãã ããã§ããããã®ããã£ããæªããªãç æ°ãã«å¯Ÿãã瀟äŒã¯åãªãæ²»çæ³ã®éçºã ãã§ãªããããå æçã§ãæè»ãªåŽåç°å¢ãåããæ Œå·®ã®æ¯æ£ã«çæ¯ã«åãçµããã¬ãžãªãšã³ããªæ§é ãžãšé²åããããšãæ±ããããŠãããæ ¢æ§çŸæ£ãšã®å ±çã¯ã21äžçŽã®æç瀟äŒãé¿ããŠã¯éããªããæå€§ã®è©Šç·Žã§ãããåæã«ç€ŸäŒããã人éäžå¿ã®åœ¢ãžãšåæ§ç¯ããæ©äŒã§ãããã
åŒçšæç®
NCDs reduce quality of life, productivity and economic growth: The ..., https://www.oecd.org/en/publications/the-health-and-economic-benefits-of-tackling-non-communicable-diseases_e20cbbc3-en/full-report/ncds-reduce-quality-of-life-productivity-and-economic-growth_f407c1af.html
The Changing Disease-Scape in the Third Epidemiological Transition - MDPI, https://www.mdpi.com/1660-4601/7/2/675
Addressing the Costs and Care for Long COVID - OECD, https://www.oecd.org/en/publications/addressing-the-costs-and-care-for-long-covid_87a0c171-en.html
World Report on Social Determinants of Health Equity, https://www.who.int/teams/social-determinants-of-health/equity-and-health/world-report-on-social-determinants-of-health-equity
Long COVID costs world's economy billions: analysis | CIDRAP - University of Minnesota, https://www.cidrap.umn.edu/covid-19/long-covid-costs-world-s-economy-billions-analysis
In the next decade, long COVID could cost health systems 11 billion ..., https://www.oecd.org/en/publications/addressing-the-costs-and-care-for-long-covid_87a0c171-en/full-report/in-the-next-decade-long-covid-could-cost-health-systems-11-billion-dollars-annually-and-cut-annual-gdp-by-0-2_da64ebac.html
Long COVID impacts health systems and the economies: Addressing the Costs and Care for ... - OECD, https://www.oecd.org/en/publications/addressing-the-costs-and-care-for-long-covid_87a0c171-en/full-report/long-covid-impacts-health-systems-and-the-economies_608d2480.html
ã什å8幎4æãããå
šãŠã®äºæ¥äž»ã®æ¹ãžãç
æ°ãæ±ããåŽåè
ã® ..., https://www.solare-sr.com/post-7920/
ããããã®å¥åº·çµå¶ã«ã€ã㊠- çµæžç£æ¥ç, https://www.meti.go.jp/policy/mono_info_service/healthcare/downloadfiles/250424_kenkoukeieigaiyou.pdf
äŒæ¥ã¯åŸæ¥å¡ã®å¥åº·ãå®ãåãçµã¿ãã2024幎床ãããå¥åº·æ¥æ¬21ïŒç¬¬äžæ¬¡ïŒããéå§ - HRãã, https://www.hrpro.co.jp/series_detail.php?t_no=3830
Digital Therapeutics for Mental Health: Global Adoption Trends and Gaps | HITLAB, https://www.hitlab.org/digital-therapeutics-mental-health-2025/
Full article: Digital therapeutics as a new weapon against diseases: focus on the current European legislation and possible therapeutic strategies - Taylor & Francis, https://www.tandfonline.com/doi/full/10.1080/17434440.2025.2457468
Reprogramming Chronic Care: AI-Driven Digital Therapeutics for a Connected, Personalized and Equitable Health Future - Journal of Pharmaceutical Technology, Research and Management, https://jptrm.chitkara.edu.in/2025/reprogramming-chronic-care-ai-driven-digital-therapeutics-for-a-connected-personalized-and-equitable-health-future/
Digital Therapeutics Market: 2025 Analysis & Growth Trends - IntuitionLabs, https://intuitionlabs.ai/articles/digital-therapeutics-market-analysis
Telemedicine and digital health: The future for pharmaceutical ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC12880784/
A systematic review of digital therapeutics: regulatory and business factors, https://www.tendenzenuove.it/2025/09/25/a-systematic-review-of-digital-therapeutics-regulatory-and-business-factors/
Digital Therapeutics (DTx) Market Trends and Future Opportunities Report [2032], https://www.congruencemarketinsights.com/press-release/digital-therapeutics-dtx-market
Social determinants of health - World Health Organization (WHO), https://www.who.int/health-topics/social-determinants-of-health
World Report on Social Determinants of Health Equity, 2025 [EN/PT ..., https://reliefweb.int/report/world/world-report-social-determinants-health-equity-2025-enpt
World report on social determinants of health equity, 2025, https://primaryhealthcare4people.org/publication/world-report-on-social-determinants-of-health-equity-2025/
Social Determinants of Health (SDOH) | About CDC, https://www.cdc.gov/about/priorities/why-is-addressing-sdoh-important.html
Social Determinants of Health and Older Adults | odphp.health.gov, https://odphp.health.gov/our-work/national-health-initiatives/healthy-aging/social-determinants-health-and-older-adults
THE SOCIAL DETERMINANTS OF HEALTH EQUITY, https://actionsdg.ctb.ku.edu/docs/2025-Factsheet-GNHiAP-Social-Determinants-of-Health-Equity.pdf
ã€ã³ã°ã±ã¢ã©ãŒãšãã®å®¶æã®æ¯æŽ - åçåŽåç, https://www.mhlw.go.jp/content/12000000/001092918.pdf
ãã€ã³ã°ã±ã¢ã©ãŒãå®¶æã®ä»è·ã¯åœããåïŒèª¿æ»ã§æããã«ãªã£ãåã©ãã»è¥è
ã®å®æ
, https://www.heartpage.jp/contents/magazine/08-00675
ã±ã¢ã©ãŒã»ã€ã³ã°ã±ã¢ã©ãŒæ¯æŽãåãå·»ã課é¡, https://toyo.repo.nii.ac.jp/record/14518/files/lifedesign18_385-399.pdf
ã€ã³ã°ã±ã¢ã©ãŒã®å®æ
ã«é¢ãã調æ»ç ç©¶ - ãã©ãå®¶åºåº, https://www.cfa.go.jp/assets/contents/node/basic_page/field_ref_resources/6666f757-7772-4156-9835-2c8bca59be64/d76831b6/20231013_policieskosodateshienchousasuishinchosar03-02_h5.pdf
(PDF) Updating the epidemiological transition model - ResearchGate, https://www.researchgate.net/publication/323882983_Updating_the_epidemiological_transition_model
The development and experience of epidemiological transition theory over four decades - Diva-portal.org, https://www.diva-portal.org/smash/get/diva2:728342/FULLTEXT01.pdf
The epidemiologic transition theory revisited thirty years later - IRIS,
